Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran.
Amirmohammad TajikShekoufeh NikfarSepideh ElyasiOmid RajabiMehdi VarmaghaniPublished in: Child and adolescent psychiatry and mental health (2023)
From a social perspective, the inclusion of LDX in the treatment regimen for ADHD is associated with higher costs and an increased financial burden. However, based on our analysis, LDX appears to be a cost-effective choice for managing ADHD in Iran when compared to MPH.
Keyphrases
- attention deficit hyperactivity disorder
- end stage renal disease
- autism spectrum disorder
- newly diagnosed
- working memory
- ejection fraction
- chronic kidney disease
- healthcare
- mental health
- peritoneal dialysis
- prognostic factors
- risk factors
- young adults
- patient reported outcomes
- smoking cessation
- affordable care act